OBJECTIVE: To investigate pazopanib hydrochloride, a multitargeted kinase inhibitor, for treatment of choroidal neovascularization (CNV). METHODS: Choroidal neovascularization was induced in mice by rupture of Bruch membrane with laser photocoagulation. Mice were treated with pazopanib by gavage or periocular injection, and the area of CNV was measured. RESULTS: Twice-daily gavage of pazopanib, 100 mg/kg, suppressed the development of CNV by 93%. Treatment of established CNV between days 7 and 14 with 8, 40, or 200 mg/kg per day reduced CNV by 0%, 58%, and 71%, respectively. Substantial regression (40%) of CNV was also achieved after periocular injection of pazopanib. A single oral dose of 4 or 100 mg/kg resulted in an area under the curve from time 0 to the last quantifiable concentration of 129.6 and 752.0 microg x h/mL, respectively. After 7 days of 4, 20, or 100 mg/kg twice a day by gavage, plasma levels were 1300, 4900, and 5800 ng/mL and levels in the retina/choroid were 4800, 28 800, and 38 000 ng/g of tissue. CONCLUSIONS: Orally administered pazopanib has good bioavailability to the retina/choroid and strongly suppresses CNV in mice. Treatment with pazopanib after CNV is established causes dose-dependent regression of CNV. CLINICAL RELEVANCE: Pazopanib may be useful for treatment of CNV in humans.
OBJECTIVE: To investigate pazopanib hydrochloride, a multitargeted kinase inhibitor, for treatment of choroidal neovascularization (CNV). METHODS: Choroidal neovascularization was induced in mice by rupture of Bruch membrane with laser photocoagulation. Mice were treated with pazopanib by gavage or periocular injection, and the area of CNV was measured. RESULTS: Twice-daily gavage of pazopanib, 100 mg/kg, suppressed the development of CNV by 93%. Treatment of established CNV between days 7 and 14 with 8, 40, or 200 mg/kg per day reduced CNV by 0%, 58%, and 71%, respectively. Substantial regression (40%) of CNV was also achieved after periocular injection of pazopanib. A single oral dose of 4 or 100 mg/kg resulted in an area under the curve from time 0 to the last quantifiable concentration of 129.6 and 752.0 microg x h/mL, respectively. After 7 days of 4, 20, or 100 mg/kg twice a day by gavage, plasma levels were 1300, 4900, and 5800 ng/mL and levels in the retina/choroid were 4800, 28 800, and 38 000 ng/g of tissue. CONCLUSIONS: Orally administered pazopanib has good bioavailability to the retina/choroid and strongly suppresses CNV in mice. Treatment with pazopanib after CNV is established causes dose-dependent regression of CNV. CLINICAL RELEVANCE: Pazopanib may be useful for treatment of CNV in humans.
Authors: K Mori; A Ando; P Gehlbach; D Nesbitt; K Takahashi; D Goldsteen; M Penn; C T Chen; K Mori; M Melia; S Phipps; D Moffat; K Brazzell; G Liau; K H Dixon; P A Campochiaro Journal: Am J Pathol Date: 2001-07 Impact factor: 4.307
Authors: M S Seo; N Okamoto; M A Vinores; S A Vinores; S F Hackett; H Yamada; E Yamada; N L Derevjanik; W LaRochelle; D J Zack; P A Campochiaro Journal: Am J Pathol Date: 2000-09 Impact factor: 4.307
Authors: S F Hackett; H Ozaki; R W Strauss; K Wahlin; C Suri; P Maisonpierre; G Yancopoulos; P A Campochiaro Journal: J Cell Physiol Date: 2000-09 Impact factor: 6.384
Authors: Magdalena G Krzystolik; Mehran A Afshari; Anthony P Adamis; Jacques Gaudreault; Evangelos S Gragoudas; Norman A Michaud; Wenjun Li; Edward Connolly; Charles A O'Neill; Joan W Miller Journal: Arch Ophthalmol Date: 2002-03
Authors: Jocelyn Holash; Sam Davis; Nick Papadopoulos; Susan D Croll; Lillian Ho; Michelle Russell; Patricia Boland; Ray Leidich; Donna Hylton; Elena Burova; Ella Ioffe; Tammy Huang; Czeslaw Radziejewski; Kevin Bailey; James P Fandl; Tom Daly; Stanley J Wiegand; George D Yancopoulos; John S Rudge Journal: Proc Natl Acad Sci U S A Date: 2002-08-12 Impact factor: 11.205
Authors: Takeshi Iwase; Jie Fu; Tsunehiko Yoshida; Daisuke Muramatsu; Akiko Miki; Noriyasu Hashida; Lili Lu; Brian Oveson; Raquel Lima e Silva; Christopher Seidel; Ming Yang; Sheila Connelly; Jikui Shen; Bing Han; Mingsheng Wu; Gregg L Semenza; Justin Hanes; Peter A Campochiaro Journal: J Control Release Date: 2013-10-12 Impact factor: 9.776
Authors: Francisco Amparo; Zahra Sadrai; Yiping Jin; Belen Alfonso-Bartolozzi; Haobing Wang; Hasanain Shikari; Joseph B Ciolino; James Chodosh; Ula Jurkunas; Debra A Schaumberg; Reza Dana Journal: Invest Ophthalmol Vis Sci Date: 2013-01-17 Impact factor: 4.799
Authors: Takeshi Iwase; Brian C Oveson; Noriyasu Hashida; Raquel Lima e Silva; Jikui Shen; Achim H Krauss; David C Gale; Peter Adamson; Peter A Campochiaro Journal: Invest Ophthalmol Vis Sci Date: 2013-01-21 Impact factor: 4.799